Roche app allows access to latest cancer guidelinesRoche has launched an app allowing access to the latest guidelines covering the most common forms of cancer. Share XRoche app allows access to latest cancer guidelineshttps://pharmaphorum.com/news/roche-app-allows-access-to-latest-cancer-guidelines/
Lilly’s $1.6bn cancer drug draws blank in pancreatic cancer trialEli Lilly is looking at other uses for its new cancer immunotherapy pegilodecakin after it flopped in a Share XLilly’s $1.6bn cancer drug draws blank in pancreatic cancer trialhttps://pharmaphorum.com/news/lillys-1-6bn-cancer-drug-draws-blank-in-pancreatic-cancer-trial/
Roche sets analysts purring with strong Q3 resultsRoche has beaten market expectations in third quarter results, with new drugs gaining traction and its older medicines Share XRoche sets analysts purring with strong Q3 resultshttps://pharmaphorum.com/news/roche-sets-analysts-purring-with-strong-q3-results/
ImaginAb joins with AZ, Pfizer and Takeda to develop tumour imaging techLA-based biotech ImaginAb has signed a multi-party agreement with pharma giants AstraZeneca, Pfizer, and Takeda, for technology that Share XImaginAb joins with AZ, Pfizer and Takeda to develop tumour imaging techhttps://pharmaphorum.com/news/imaginab-joins-with-az-pfizer-and-takeda-to-develop-tumour-imaging-tech/
GSK joins with US biotech to toughen up cell therapies for solid tumoursGlaxoSmithKline has announced a five-year collaboration with San Francisco biotech Lyell Immunopharma, to strengthen therapeutic T-cells before they Share XGSK joins with US biotech to toughen up cell therapies for solid tumourshttps://pharmaphorum.com/news/gsk-joins-with-us-biotech-to-toughen-up-cell-therapies-for-solid-tumours/
The state of personalised medicine in 2019Things are good, and they’re getting better. When researchers completed mapping the human genome in 2003, it broke Share XThe state of personalised medicine in 2019https://pharmaphorum.com/views-analysis-oncology/the-state-of-personalised-medicine-in-2019/
ESMO 2019 roundupThe European Society for Medical Oncology (ESMO) is growing in stature, with an increasing number of oncology-focused pharma Share XESMO 2019 rounduphttps://pharmaphorum.com/views-analysis-oncology/esmo-2019-roundup/
Merck & Co hopes for foothold in early TNBC after Keytruda trial winMerck & Co has unveiled data from its immunotherapy Keytruda that could allow it to gain a foothold Share XMerck & Co hopes for foothold in early TNBC after Keytruda trial winhttps://pharmaphorum.com/news/merck-co-hopes-for-foothold-in-early-tnbc/
Clovis signs radiopharmaceuticals R&D deal with German biotech 3BClovis Oncology has become the latest pharma to invest in radiopharmaceuticals, signing a licensing and collaboration deal with Share XClovis signs radiopharmaceuticals R&D deal with German biotech 3Bhttps://pharmaphorum.com/news/clovis-signs-radiopharmaceuticals-rd-deal-with-german-biotech-3b/
